Highest-materiality recent filing
10x Genomics Q2 revenue $151M (+3% ex-settlements); raises FY2026 guidance to $610-630M
Revenue $151.0M, up 3% YoY excluding patent settlement revenue; gross margin 74% vs 72%.
10x Genomics Q1 2026 net loss narrows to $13.5M; launches Atera platform
Revenue $150.8M (-3% YoY); +9% excluding $16.8M one-time license/royalty in Q1 2025.
10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M
Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).
Q4 consumables rev $141.7M (+6% YoY); Spatial consumables up 14% YoY to $41.0M.
10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M
Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.
10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M
Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).
10x Genomics settles patent litigation with Bruker; to receive $68M upfront plus royalties
Settled all patent litigation with Bruker (formerly NanoString) regarding spatial biology platforms; all claims dismissed with prejudice.
10x Genomics revenue ex-settlement falls 2% YoY; cuts 8% workforce, withdraws FY guidance
Q1 revenue $154.9M incl $16.8M patent settlement; ex-settlement $138.1M, down 2% YoY.
10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat
Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).
10x Genomics Q3 revenue $151.7M (-1% YoY); cuts FY2024 revenue guidance to $595-605M
Revenue $151.7M, down 1% YoY; net loss improved to $35.8M from $93.0M.
10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%
Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).
Q2 revenue $153.1M, +4% YoY; net loss $37.9M vs $62.4M loss in prior year.
10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed
Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.
10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth
Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).
CCO James Wilbur to depart 10x Genomics on Feb 1, 2024; gets severance
James Wilbur, Chief Commercial Officer, leaving effective Feb 1, 2024; no disagreement with management.
10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%
Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.
10x Genomics Q3 revenue $153.6M (+17% YoY), net loss $93.0M; raises FY2023 guidance
Q3 2023 revenue $153.6M, up 17% YoY; raised FY2023 guidance to $610-625M.
10x Genomics Q2 revenue $146.8M (+28% YoY); raises FY2023 guidance to $600-620M
Revenue $146.8M in Q2, +28% YoY from $114.6M.
10x Genomics wins permanent German injunction against NanoString's CosMx products
Munich Regional Court issued permanent injunction requiring NanoString to stop selling CosMx SMI instruments and RNA detection reagents in Germany.
10x Genomics Q1 revenue $134.3M (+17% YoY); net loss $50.7M; raises FY2023 guidance to $590-$610M
Revenue $134.3M (+17% YoY); spatial portfolio drove growth, Xenium in first full launch quarter.
10x Genomics Q4 revenue up 9% to $156.2M; FY net loss triples to $166M, guides FY23 rev $580-600M
Q4 2022 revenue $156.2M (+9% YoY); FY 2022 revenue $516.4M (+5% YoY).
10x Genomics Q3 revenue up 5% to $131.1M but net loss widens to $41.9M
Revenue $131.1M (+5% YoY, +14% QoQ); gross margin 77% (down from 80% in Q3 2021).
10x Genomics Q2 revenue $114.6M (-1% YoY); net loss $64.5M vs $11.1M loss
Revenue $114.6M, down 1% YoY; gross margin 76% vs 96% due to $14.7M prior-year royalty reversal.
10x Genomics preannounces Q2 rev ~$114.5M (-1% YoY), hires Jim Wilbur as CCO
Preliminary Q2 rev of ~$114.5M, down ~1% YoY from $115.8M and flat sequentially.
10x Genomics Q1 revenue $114.5M (+8% YoY); net loss widens to $42.4M; FY22 guidance maintained
Revenue $114.5M, up 8% YoY from $105.8M; gross margin fell to 78% from 84%.
10x Genomics reports FY 2021 revenue $490.5M (+64% YoY); guides FY 2022 revenue $600-630M
Revenue $490.5M FY 2021, up 64% from $298.8M in FY 2020; Q4 revenue $143.5M, up 28% from $112.2M.
10x Genomics Q3 revenue $125.3M (+74% YoY); FY2021 guidance raised to $490-500M
Revenue $125.3M, up 74% YoY and 8% QoQ; operating loss $15.9M vs $65.3M loss last year.
10x Genomics Q2 revenue $115.8M (+170% YoY); settles Bio-Rad litigation
Revenue $115.8M, up 170% YoY and 9% QoQ; net loss narrowed to $11.1M from $40.2M.
Cross license covers single cell analysis; excludes spatial, in situ, and digital PCR (for 10x).
On October 24, 2024, Mathai Mammen informed the Company of his decision to resign as a member of the Board of Directors
Justin J. McAnear, who on August 6, 2024 notified the Company of his intention to resign and who will continue to provide transition services as an employee of the Company through August 30, 2024.
On August 8, 2024, the Company announced that Adam S. Taich will be joining the Company as its Chief Financial Officer, effective August 12, 2024, replacing Justin J. McAnear
On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.
appointed Alan V. Mateo to the Board of Directors as a Class II director effective immediately
On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.
On July 18, 2023, Bryan E. Roberts informed 10x Genomics, Inc. (the "Company") of his decision to resign as a member of the Board of Directors (the "Board") of the Company, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately.
Max materiality 0.85 · Median 0.70 · Most common event earnings